ArticleInternational journal for parasitology. Drugs and drug resistance2018
Assessment of Draxxin
Article in International journal for parasitology. Drugs and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Targeting piroplasmosis and theileriosis: New frontiers in drug development.Tropical animal health and production · 2025Pooled it
- Enhanced Anti-Babesia Efficacy of Buparvaquone and Imidocarb When Combined with ELQ-316 In Vitro Culture ofPharmaceuticals (Basel, Switzerland) · 2025Article
- The Combination of Buparvaquone and ELQ316 Exhibit a Stronger Effect than ELQ316 and Imidocarb AgainstPharmaceutics · 2024Article
- New insights in the diagnosis and treatment of equine piroplasmosis: pitfalls, idiosyncrasies, and myths.Frontiers in veterinary science · 2024Review
- Comparative efficacy of buparvaquone and imidocarb in inhibiting theFrontiers in pharmacology · 2024Article
- Tulathromycin and Diclazuril Lack Efficacy againstPathogens (Basel, Switzerland) · 2023Article
- A TransfectedPathogens (Basel, Switzerland) · 2022Article
- A Culture-Adapted Strain ofFrontiers in cellular and infection microbiology · 2022Article
- Establishment ofPathogens (Basel, Switzerland) · 2021Article
- Development of an Indirect ELISA to Detect Equine Antibodies toPathogens (Basel, Switzerland) · 2021Article
- Bovine Babesiosis in Turkey: Impact, Current Gaps, and Opportunities for Intervention.Pathogens (Basel, Switzerland) · 2020Review
- Imidocarb Dipropionate Lacks Efficacy againstPathogens (Basel, Switzerland) · 2020Article
- Twenty Years of Equine Piroplasmosis Research: Global Distribution, Molecular Diagnosis, and Phylogeny.Pathogens (Basel, Switzerland) · 2020Review
- Exposure to ambient air causes degradation and decreasedVeterinary parasitology: X · 2020Article
- Unravelling the cellular and molecular pathogenesis of bovine babesiosis: is the sky the limit?International journal for parasitology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Babesia bovis, Babesia bigemina and Theileria equi are worldwide tick-borne hemoprotozoan that cause diseases characterized by fever, anemia, weight loss and abortion. A common feature of these diseases are transition from acute to chronic phases, in which parasites may persist in the host for life, and becoming a reservoir for tick transmission. The live-attenuated vaccines for B. bovis and B. bigemina are not available for worldwide use due to legal restrictions and other concerns such as potential erythrocyte antigen and pathogen contamination, and a vaccine for T. equi is not available. The use of chemotherapeutics is essential to treat and control these diseases, but several studies have shown the development of drug-resistance by these parasites, and safe and effective alternative drugs are needed. Tulathromycin, a macrolide antibiotic, has proven to be effective against a vast range of bacteria and Plasmodium yoelli, a Babesia and Theileria related intra-erythrocytic apicomplexan. Draxxin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.